-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: federally funded research
Research!America Report: Investment in Health Research Remains Stagnant
By Research!America The U.S. public and private sectors invested $140.5 billion in 2010 on research to find new ways to treat, cure and prevent disease and disability, according to Research!America’s latest annual estimate. Health research spending accounted for only 5.5% of the $2.6 trillion the U.S. spent on health care in 2010. Health research as a percentage of health care spending has hovered around 5.5% since 2005, remaining essentially stagnant. Investment in health research experienced Read More >
Raising the Stakes in Biotech
Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >
Bayh Dole Act a Failure? Part II: The Comments
By Guest Joseph Allen Yesterday we posted the reply of Robin Rasor, President of the Assn of University Technology Managers, to a Washington Post opinion piece by Vivek Wadhwa asserting that the university/industry technology transfer model established under the Bayh-Dole Act had failed and should be replaced. The article set off a series of comments, the most interesting of which occurred when Mr Wadhwa challenged Rasor to document the statistics she used asserting the Bayh-Dole Read More >
AUTM’s 2010 Better World Report Highlights
AUTM released their Better World Report for 2010 highlighting academic innovations commercially developed through technology transfer that are improving the quality of life. Here is a quote from their press release. A device that allows the blind to ―see‖ via electrical pulses applied to the tongue…a collagen scaffold to treat damaged joints…a new vaccine to prevent shingles…an artificial lung that provides patients with both mobility and comfort during treatment…a program that vastly improves literacy among Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
